Format

Send to

Choose Destination
Mol Ther. 2016 Aug;24(8):1470-7. doi: 10.1038/mt.2016.83. Epub 2016 Apr 25.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.

Author information

1
Medical Research Council Unit, Fajara, The Gambia.
2
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
3
The Jenner Institute Laboratories, University of Oxford, Oxford, UK.
4
Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, Churchill Hospital, Oxford, UK.
5
Keires AG, Bäumleingasse, Basel, Switzerland.
6
ReiThera, Rome, Italy.
7
CEINGE, Naples, Italy.
8
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
9
European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
10
Current address: Department of Immunology, Monash University, Prahran, Melbourne, Australia.
11
Kenya Medical Research Institute, Centre for Geographical Medical Research (Coast), Kilifi, Kenya.

Abstract

Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.

PMID:
27109630
PMCID:
PMC5010143
DOI:
10.1038/mt.2016.83
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center